Frontlight ResearchEarly access
Taking people in United StatesNo phase
Mucopolysaccharidosis VII Disease Monitoring Program
Key facts
- Who runs it
- Ultragenyx Pharmaceutical Inc
- Where
- Ann Arbor, Chicago, New York, Orange, Salt Lake City, Seattle, and Washington D.C., United StatesSee the 7 sitesAlso in 7 other countries, 7 sites
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 29 Jan 2018
- Expected to end
- Apr 2032
- Type of study
- Observational, 2 groups
- Record updated
- 27 August 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis
- Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients >18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures
- Willing to comply with DMP visit schedule
Who cannot take part
- Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx
This trial is currently available in United States.
Also in 7 other countries, 7 sites
- University of MichiganAnn Arbor, United StatesTaking people
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesTaking people
- New York University Langone Medical CenterNew York, United StatesNo longer taking part
- Children's Hospital of Orange CountyOrange, United StatesTaking people
- University of Utah Medical CenterSalt Lake City, United StatesTaking people
- Seattle Children's HospitalSeattle, United StatesTaking people
- Children's National Health SystemWashington D.C., United StatesTaking people
About the trial
What the trial wants to find out
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
The 2 groups in the trial
- Patients with MPS VII receiving vestronidase-alfa
via prescription, or early access/ compassionate use program
- Patients with MPS VII not receiving vestronidase-alfa
no treatment or treatment other than vestronidase alfa
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
- Record updated
- 27 August 2026